Zealand Pharma A/S
CSE:ZEAL
Zealand Pharma A/S
Total Liabilities & Equity
Zealand Pharma A/S
Total Liabilities & Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Total Liabilities & Equity
kr9.5B
|
CAGR 3-Years
66%
|
CAGR 5-Years
43%
|
CAGR 10-Years
32%
|
|
|
Genmab A/S
CSE:GMAB
|
Total Liabilities & Equity
kr45.8B
|
CAGR 3-Years
23%
|
CAGR 5-Years
25%
|
CAGR 10-Years
32%
|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Total Liabilities & Equity
€1.2B
|
CAGR 3-Years
3%
|
CAGR 5-Years
12%
|
CAGR 10-Years
35%
|
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Total Liabilities & Equity
kr14.4B
|
CAGR 3-Years
6%
|
CAGR 5-Years
15%
|
CAGR 10-Years
23%
|
|
|
Bioporto A/S
CSE:BIOPOR
|
Total Liabilities & Equity
kr96m
|
CAGR 3-Years
6%
|
CAGR 5-Years
18%
|
CAGR 10-Years
10%
|
|
|
Saniona AB
STO:SANION
|
Total Liabilities & Equity
kr339.7m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
29%
|
CAGR 10-Years
36%
|
|
Zealand Pharma A/S
Glance View
Zealand Pharma A/S is a Danish biotechnology company that has carved a niche in the medical field by focusing on the design and development of innovative peptide-based medicines. Established in 1998 and headquartered in Copenhagen, the company is driven by a singular mission: to improve patients' lives through impactful treatments. Zealand's expertise lies in peptide therapeutics, a compelling segment of biopharmaceuticals due to their ability to mimic biological processes with high specificity and efficacy. The company has a keen focus on addressing unmet medical needs, particularly in the treatment of metabolic and gastrointestinal diseases. With a robust pipeline that ranges from early-stage research to late-stage clinical trials, Zealand Pharma leverages its proprietary technology to discover and develop novel pharmaceuticals that can be game-changers in their respective therapeutic areas. Zealand Pharma's business model centers around the development and commercialization of its proprietary medicines, both independently and through strategic partnerships. By collaborating with larger pharmaceutical companies, Zealand enhances its global commercialization capabilities and mitigates the financial risks inherent in drug development. For instance, the company has partnered with multinational corporations, allowing it to tap into resources for advanced research, regulatory processes, and worldwide distribution systems. Revenue streams are diversified through milestone payments, royalties, and direct sales, ensuring a steady inflow of cash that supports continued innovation. This strategic approach not only sustains its operations but also propels its mission of delivering transformative healthcare solutions. In essence, Zealand Pharma thrives at the confluence of science and strategy, driving both its financial health and its contributions to the biopharmaceutical landscape.
See Also
What is Zealand Pharma A/S's Total Liabilities & Equity?
Total Liabilities & Equity
9.5B
DKK
Based on the financial report for Dec 31, 2024, Zealand Pharma A/S's Total Liabilities & Equity amounts to 9.5B DKK.
What is Zealand Pharma A/S's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 10Y
32%
Over the last year, the Total Liabilities & Equity growth was 380%. The average annual Total Liabilities & Equity growth rates for Zealand Pharma A/S have been 66% over the past three years , 43% over the past five years , and 32% over the past ten years .
You don't have any saved screeners yet